SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 6, 2012, Pages 714-723

  Rajan, Sindhu ^a   Torres, Jacqueline ^a   Thompson, Michael S ^a   Philipson, Louis H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

5' cyclic monophosphate; Adenosine 3'; Glucagon like peptide 1 receptor; Insulin secretion; Sumoylation

Indexed keywords

CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INCRETIN; SUMO PROTEIN; UBIQUITIN CONJUGATING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; INSULIN RELEASE; INSULINOMA; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUMOYLATION;

ANIMALS; BIOTINYLATION; CELLS, CULTURED; CYCLIC GMP; DNA, COMPLEMENTARY; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT ANTIBODY TECHNIQUE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; IMMUNOPRECIPITATION; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; STIMULATION, CHEMICAL; TRANSFECTION; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84858173194     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00486.2011.     Document Type: Article

References (38)

1. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ, Kim KW. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys Res Commun 324: 394-400, 2004.
2. Benson MD, Li QJ, Kieckhafer K, Dudek D, Whorton MR, Sunahara RK, Iniguez-Lluhi JA, Martens JR. SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5. Proc Natl Acad Sci USA 104: 1805-1810, 2007.
3. Bossis G, Chmielarska K, Gartner U, Pichler A, Stieger E, Melchior F. A fluorescence resonance energy transfer-based assay to study SUMO modification in solution. Methods Enzymol 398: 20-32, 2005.
4. Comerford KM, Leonard MO, Cummins EP, Fitzgerald KT, Beullens M, Bollen M, Taylor CT. Regulation of protein phosphatase 1gamma activity in hypoxia through increased interaction with NIPP1: implications for cellular metabolism. J Cell Physiol 209: 211-218, 2006.
5. Dai XQ, Kolic J, Marchi P, Sipione S, Macdonald PE. SUMOylation regulates Kv2.1 and modulates pancreatic beta-cell excitability. J Cell Sci 122: 775-779, 2009.
6. Dai XQ, Plummer G, Casimir M, Kang Y, Hajmrle C, Gaisano HY, Manning Fox JE, MacDonald PE. SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans. Diabetes 60: 838-847, 2011.
7. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell 2: 233-239, 1998.
8. Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 1: 22-31, 2005.
9. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagonlike peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84: 3434-3438, 1987.
10. 2+and G protein-coupled receptors in the pancreatic β-cell: a computational approach. Am J Physiol Cell Physiol 293: C1924-C1933, 2007.
11. Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8: 947-956, 2007.
12. Gromada J, Dissing S, Rorsman P. Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKAindependent mechanisms. Br J Pharmacol 118: 769-775, 1996.
13. Hansen KB, Vilsboll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 95: 3309-3317, 2010.
14. Jacobson DA, Kuznetsov A, Lopez JP, Kash S, Ammala CE, Philipson LH. Kv2.1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion. Cell Metab 6: 229-235, 2007.
15. Kaukinen P, Vaheri A, Plyusnin A. Non-covalent interaction between nucleocapsid protein of Tula hantavirus and small ubiquitin-related modifier-1, SUMO-1. Virus Res 92: 37-45, 2003.
16. Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, Holst JJ, Krarup T. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56: 1951-1959, 2007.
17. Landa LR Jr, Harbeck M, Kaihara K, Chepurny O, Kitiphongspattana K, Graf O, Nikolaev VO, Lohse MJ, Holz GG, Roe MW. Interplay of Ca2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line. J Biol Chem 280: 31294-31302, 2005.
18. Lee YS, Jang MS, Lee JS, Choi EJ, Kim E. SUMO-1 represses apoptosis signal-regulating kinase 1 activation through physical interaction and not through covalent modification. EMBO Rep 6: 949-955, 2005.
19. Li X, Vadrevu S, Dunlop A, Day J, Advant N, Troeger J, Klussmann E, Jaffrey E, Hay RT, Adams DR, Houslay MD, Baillie GS. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochem J 428: 55-65, 2010.
20. Lisenbee CS, Miller LJ. Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Biochemistry 45: 8216-8226, 2006.
21. Manza LL, Codreanu SG, Stamer SL, Smith DL, Wells KS, Roberts RL, Liebler DC. Global shifts in protein sumoylation in response to electrophile and oxidative stress. Chem Res Toxicol 17: 1706-1715, 2004.
22. Martin S, Nishimune A, Mellor JR, Henley JM. SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature 447: 321-325, 2007.
23. Merrill JC, Melhuish TA, Kagey MH, Yang SH, Sharrocks AD, Wotton D. A role for non-covalent SUMO interaction motifs in Pc2/ CBX4 E3 activity. PLoS One 5: e8794, 2010.
24. Mziaut H, Kersting S, Knoch KP, Fan WH, Trajkovski M, Erdmann K, Bergert H, Ehehalt F, Saeger HD, Solimena M. ICA512 signaling enhances pancreatic beta-cell proliferation by regulating cyclins D through STATs. Proc Natl Acad Sci USA 105: 674-679, 2008.
25. Nauck MA, Meier JJ. Individualised incretin-based treatment for type 2 diabetes. Lancet 376: 393-394, 2010.
26. Palacios S, Perez LH, Welsch S, Schleich S, Chmielarska K, Melchior F, Locker JK. Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its selfassociation. Mol Biol Cell 16: 2822-2835, 2005.
27. Plant LD, Dementieva IS, Kollewe A, Olikara S, Marks JD, Goldstein SA. One SUMO is sufficient to silence the dimeric potassium channel K2P1. Proc Natl Acad Sci USA 107: 10743-10748, 2010.
28. Plant LD, Dowdell EJ, Dementieva IS, Marks JD, Goldstein SA. SUMO modification of cell surface Kv2.1 potassium channels regulates the activity of rat hippocampal neurons. J Gen Physiol 137: 441-454, 2011.
29. Rajan S, Eames SC, Park SY, Labno C, Bell GI, Prince VE, Philipson LH. In vitro processing and secretion of mutant insulin proteins that cause permanent neonatal diabetes. Am J Physiol Endocrinol Metab 298: E403-E410, 2010.
30. + channel K2P1. Cell 121: 37-47, 2005.
31. Salehi M, Aulinger BA, D'Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 29: 367-379, 2008.
32. Shao C, Cobb MH. Sumoylation regulates the transcriptional activity of MafA in pancreatic beta cells. J Biol Chem 284: 3117-3124, 2009.
33. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 18: 2388-2399, 2009.
34. Song Y, Madahar V, Liao J. Development of FRET assay into quantitative and high-throughput screening technology platforms for proteinprotein interactions. Ann Biomed Eng 39: 1224-1234, 2011.
35. Tatham MH, Hay RT. FRET-based in vitro assays for the analysis of SUMO protease activities. Methods Mol Biol 497: 253-268, 2009.
36. Tempe D, Piechaczyk M, Bossis G. SUMO under stress. Biochem Soc Trans 36: 874-878, 2008.
37. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King GL, Weir GC, Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56: 1551-1558, 2007.
38. Zhang H, Smolen GA, Palmer R, Christoforou A, van den Heuvel S, Haber DA. SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2. Nat Genet 36: 507-511, 2004.